Situation:

Case count as of June 3, 2021 / Nombre de cas le 3 juin 2021

Area / Région	Area / Région	Change from yesterday / Changement par rapport à hier	Deaths / Décès	Change from yesterday / Changement par rapport à hier
Canada*	1 385 278	+ 2 064	25 612	+  46
Ontario**	533 761	+  870	+ 8 801	+  10

* Numbers from PHAC current as of 7 p.m. yesterday / Chiffres de l’ASPC à jour à 19h hier.

** Ontario current as of 3 p.m. yesterday / Chiffres de l’Ontario à jour à 15h hier.

 

Ontario:

Vaccination*	Vaccination		Yesterday / Hier
Cumulative vaccine doses administered	Nombre total de doses de vaccin administrées		9 493 005
Confirmed Cases	Cas confirmés	Data Source / Source des données	Yesterday / Hier	7-day % change / % de changement sur 7 jours
Cumulative Cases	Nombre cumulatif de cas	CCM / SPGCC	533 761	1%
Health Sector Worker Cases	Nombre de cas chez les travailleurs du secteur de la santé	CCM / SPGCC	23 289	1%
7 day confirmed cases and deaths / Cas confirmes en 7 jour
Cumulative Resolved	Nombre cumulatif de cas résolus	CCM / SPGCC	514 999	3%
Cumulative Deaths	Nombre cumulatif de décès	CCM / SPGCC	8 801	1%
Long-Term Care Home Residents	Nombre de décès de résidents des CSLD	Ontario.ca: Status of COVID-19 cases in LTCH		Ontario.ca: État des cas de COVID-19 en FSLD
Retirement Home Residents	Nombre de décès de résidents des maisons de retraite	RHRA Dashboard		Tableau de bord de l’ORMR
Health Sector Worker	Nombre de décès de travailleurs du secteur de la santé	CCM / SPGCC	18	0%
Daily Count / Nombre quotidien
Effective Reproduction Number (Rt)* and Confidence Interval	Taux de reproduction effectif (Re)* et intervalle de confiance	Data Source / Source des données	May 28, 2021 – June 3, 2021 / 28 mai, 2021 – 3 juin, 2021	May 26, 2021 – June 1, 2021 / 26 mai, 2021 – 1 juin, 2021
Ontario	Ontario	PHO / SPO	0.77 [0.75 – 0.79]	0.74 [0.72 – 0.75]
North	Nord	PHO / SPO	1.00 [0.90 – 1.11]	0.91 [0.81 – 1.01]
Eastern	Est	PHO / SPO	0.84 [0.77 – 0.92]	0.83 [0.76 – 0.91]
Central East	Centre-Est	PHO / SPO	0.71 [0.69 – 0.74]	0.70 [0.68 – 0.73]
Toronto	Toronto	PHO / SPO	0.73 [0.70 – 0.77]	0.68 [0.65 – 0.72]
South West	Sud-Ouest	PHO / SPO	0.83 [0.76 – 0.91]	0.79 [0.72 – 0.86]
Central West	Centre-Ouest	PHO / SPO	0.85 [0.81 – 0.90]	0.79 [0.75 – 0.84]
Testing	Dépistage		Yesterday / Hier	7-day average / Moyenne de 7 jours
Daily tests completed	Dépistages quotidiens effectués	NOC / COR	34 277	29 360
% positivity	% de positivité	NOC / COR	2.8%	3.5%
Tests in process	Analyses en cours	NOC / COR	15 700	13 813
Daily Count 7-day % positivity / Nombre quotidien
Daily Count / Nombre quotidien
Acute Care	Soins aigus	Data Source / Source des données	Yesterday / Hier	7-day % change / % de changement sur 7 jours
Confirmed patients hospitalized	Cas confirmés hospitalisés	dBCS / RqL	729	-32%
Cumulative hospitalized health sector workers	Nombre cumulatif de travailleurs du secteur de la santé hospitalisés	CCM / SPGCC	447	1%
Cumulative health sector workers in ICU	Nombre cumulatifs de travailleurs du secteur de la santé aux soins intensifs	CCM / SPGCC	97	1%
				7-day average / Moyenne de 7 jours
Current vented patients (includes COVID+)	Patients actuellement branchés à un respirateur (incluent les COVID+)	CCSO / SOSMPC	851	871
CRCI Vented	COVID+ sur respirateur	CCSO / SOSMPC	371	408
Daily Count / Nombre quotidien

Daily Count current confirmed cases hospitalized / Nombre quotidien

Congregate Care / Habitations collectives

Active Outbreaks	Éclosions actives	Data Source / Source des données	Yesterday / Hier	7-day average / Moyenne de 7 jours
LTCH	FLSD	CCM / SPGCC	23	27
RH	MR	CCM / SPGCC	12	16
Hospital	Hôpital	CCM / SPGCC	8	15
Congregate Living / Hébergement collectif
Group Homes / Supportive Housing	Foyers de groupe / logement avec services de soutien	CCM / SPGCC	28	29
Shelter	Refuge	CCM / SPGCC	13	17
Correctional Facilities	Établissements correctionnels	CCM / SPGCC	5	5
Short-term Accommodation	Logement temporaire	CCM / SPGCC	0	0
Other congregate	Autre hébergement collectif	CCM / SPGCC	5	5
Education / Éducation
Childcare	Garde d’enfants	CCM / SPGCC	34	48
Elementary school	École élémentaire	CCM / SPGCC	4	4
Secondary school	École secondaire	CCM / SPGCC	1	1
Elementary/Secondary school	École élémentaire/secondaire	CCM / SPGCC	0	0
Post-Secondary	Postsecondaire	CCM / SPGCC	4	4
Workplaces / Lieu de travail
Farm	Exploitation agricole	CCM / SPGCC	5	7
Food Processing	Transformation alimentaire	CCM / SPGCC	8	9
Retail	Vente au détail	CCM / SPGCC	29	35
Medical/Health Service	Service médical / de santé	CCM / SPGCC	6	6
Other Workplace	Autre lieu de travail	CCM / SPGCC	119	140
Recreational / Loisir
Bar / Restaurant / Nightclub	Bar / restaurant / boîte de nuit	CCM / SPGCC	14	17
Recreational Fitness	Activités de conditionnement physique récréatives	CCM / SPGCC	2	3
Personal Service Setting	Établissement de services personnels	CCM / SPGCC	0	0
Other recreational setting	Autre établissement de loisir	CCM / SPGCC	9	11
Other / Autre
Other	Autre	CCM / SPGCC	4	4
Undefined	Indéfini	CCM / SPGCC	4	5
CCM = Provincial Case and Contact Management Solution; PHO = Public Health Ontario; NOC = COVID19 Provincial Diagnostic Network Operations Centre; CCSO = Critical Care Services Ontario; dBCS = Daily Bed Census; CRCI = COVID-Related Critical Illness (COVID-Related Critical Illness (CRCI) is defined as: Admission to the ICU because of a clinical syndrome consistent with COVID, AND the patient has had a positive test that is consistent with acute COVID illness. COVID+ is a sub-set of CRCI patients whose last COVID test was positive.) *Effective reproduction number (Rt) is updated twice weekly and not daily.  Rt is not calculated for PHU Regions with case counts < 12 over the reporting period. SPGCC= Système provincial de gestion des cas et des contacts; SPO = Santé publique Ontario; COR = Centre des opérations du réseau provincial de diagnostic de la COVID-19; SOSMPC = Services ontariens des soins aux malades en phase critique; RqL = Recensement quotidien des lits; MGLC = maladie grave liée à la COVID-19 ( une maladie grave liée à la COVID-19 s’entend d’une maladie entraînant l’admission aux soins intensifs en raison d’un syndrome clinique correspondant à la COVID-19, ET le résultat du dépistage concorde avec une COVID-19 active. COVID+ est une série secondaire de patients dont le dernier dépistage de la COVID a été positif.) *Le taux de reproduction effectif (Re) est mis à jour deux fois par semaine et non pas quotidiennement. Le Re n’est pas calculé pour les régions desservies par les BSP enregistrant < 12 cas pendant la période visée par le rapport. Data are provided in English format / Le format des chiffres est le format anglo-saxon

Update

• Ontario Updating AstraZeneca Second Dose Guidance. The Ontario government, in consultation with the Chief Medical Officer of Health and other health experts, is providing updated guidance for individuals who received the first dose of the AstraZeneca vaccine and who have not yet received their second dose, to allow for the mixing of COVID-19 vaccines if desired. This decision is in alignment with updated guidance from the National Advisory Committee on Immunization (NACI) recommendation.
• Considerations for Antigen Point-of-Care Testing has been updated and is available on the Ministry’s website.
• Given the international reports and attention relating to myocarditis and pericarditis following vaccination with mRNA COVID-19 vaccines, the Public Health Agency of Canada has prepared the attached communique. COVID-19 vaccines continue to be recommended. More information will be shared as it becomes available. To report an Adverse Event Following Immunization in Ontario, please complete the Ontario AEFI reporting form and send this to your local Public Health Unit.

Mise à jour

• L’Ontario met à jour les directives concernant la seconde dose d’AstraZeneca. Le gouvernement de l’Ontario, en consultation avec le médecin hygiéniste en chef et d’autres experts de la santé, fournit des directives mises à jour pour les personnes qui ont reçu la première dose du vaccin d’AstraZeneca et qui n’ont pas encore reçu leur seconde dose, afin de permettre la combinaison des vaccins contre la COVID-19, si elles le souhaitent. Cette décision est conforme aux recommandations mises à jour du Comité consultatif national de l’immunisation (CCNI).
• Facteurs à considérer pour les tests antigéniques au point de service a été mis à jour et affiché sur le site Web du ministère.
• Compte tenu des rapports internationaux et de l’attention accordée à la myocardite et à la péricardite à la suite de la vaccination avec les vaccins contre la COVID-19 à ARNm, l’Agence de la santé publique du Canada a préparé le communiqué ci-joint. Les vaccins contre la COVID-19 continuent d’être recommandés. D’autres renseignements seront communiqués dès qu’ils seront disponibles. Pour signaler une manifestation clinique inhabituelle à la suite d’une immunisation en Ontario, veuillez remplir le formulaire de déclaration de manifestations cliniques inhabituelles à la suite d’une immunisation en Ontario et l’envoyer à votre circonscription sanitaire locale.

 

Looking for more information?

• For more information about cases and deaths in Ontario over the course of this pandemic, and for breakdowns by region, age, and sex, please view the Government of Ontario website or the Ontario COVID-19 Data Tool by Public Health Ontario.
• Please visit the ministry website for sector-specific guidance and directives, memorandums and other resources.

 

Vous cherchez d’autres renseignements?

 

• Pour obtenir d’autres renseignements sur les cas et les décès en Ontario pendant cette pandémie, et pour connaître la répartition par région, âge et sexe, consultez le site Web du gouvernement de l’Ontario ou l’Outil de données de l’Ontario sur la COVID-19 publié par Santé publique Ontario.
• Consultez le site Web du Ministère pour obtenir le document d’orientation ainsi que les directives, notes de service et autres ressources particulières au secteur.

Communique to health practitioners

Reports of Myocarditis/pericarditis after COVID-19 vaccination (June 3, 2021).

Printable PDF version.

Background

In May 2021, international reports¹ of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) following vaccination with COVID-19 mRNA vaccines emerged, including from Israel and the United States².

Available information indicates that:

• Cases were more commonly reported after the second dose
• Symptom onset was typically within several days after vaccination
• Cases were mainly adolescents and young adults
• Cases were more often males compared to females
• Cases experienced mild illness, responded well to conservative treatment and rest, and their symptoms improved

Follow-up on these cases is ongoing. No clear association has been established between myocarditis/pericarditis and mRNA vaccines, and to date, no regulatory action has been taken in Canada or internationally.

 

 

Situation in Canada

As part of ongoing COVID-19 vaccine safety efforts, the Public Health Agency of Canada (PHAC) and Health Canada are closely monitoring myocarditis/pericarditis in passive and active Canadian safety surveillance systems, including the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS)³, the Canada Vigilance Program (CV)⁴, the Canadian National Vaccine Safety Network (CANVAS)⁵ and the Canadian Immunization Monitoring Program ACTive (IMPACT)⁶.

In Canada, there have been a small number of reports of pericarditis or myocarditis⁷, following vaccination with a COVID-19 mRNA vaccine, however it is important to note that adverse events occurring after vaccination are not necessarily related to the vaccine. Based on the few reports received in Canada, we are not currently seeing higher rates than would be expected in the general population. The Canadian weekly online adverse events report⁸ provides updates on the latest numbers.

 

 

Diagnosis and reporting

Myocarditis and pericarditis both involve inflammation of the heart in response to an infection or some other trigger. Symptoms can include shortness of breath, chest pain, or the feeling of a rapid or abnormal heart rhythm.

Healthcare providers should consider myocarditis and pericarditis in evaluation of acute chest pain or pressure, arrhythmias, shortness of breath or other clinically compatible symptoms after vaccination. They should consider doing an electrocardiogram (ECG), troponins, and an echocardiogram, in consultation with a cardiologist. It would also be important to rule out other potential causes of myocarditis and pericarditis, as such, consultation with infectious disease and/or rheumatology is recommended, to assist in this evaluation, particularly for acute COVID-19 infection (e.g., PCR testing), prior SARS-CoV-2 infection (e.g., detection of SARS-CoV-2 nucleocapsid antibodies), and other viral etiologies (e.g., enterovirus PCR and comprehensive respiratory viral pathogen testing).

All cases of myocarditis or pericarditis following vaccination should be reported to the local health authority⁹. Health Canada, PHAC, and the provincial and territorial health authorities will continue to closely monitor reports of myocarditis and/or pericarditis. Health Canada is also working closely with the manufacturers and international regulators to review information as it becomes available and will take appropriate action as needed. More information will be shared as it becomes available.

The benefits of the mRNA vaccines continue to outweigh their risks in the authorized populations, as there are clear benefits of mRNA vaccines in reducing deaths and hospitalizations due to COVID-19 infections.

 

References and links

 

1. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines. https://www.who.int/news/item/26–05-2021-gacvs-myocarditis-reported-with-covid-19- mrna-vaccines
2. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html
3. Canadian Adverse Events Following Immunization Surveillance System (CAEFISS). https://www.canada.ca/en/public–health/services/immunization/canadian-adverse-?utm_source=sefpo events-following-immunization-surveillance-system-caefiss.html
4. Canada Vigilance Program. https://www.canada.ca/en/health-canada/services/drugs-?utm_source=sefpo health-products/medeffect-canada/canada-vigilance-program.html
5. Canadian National Vaccine Safety Network (CANVAS). https://cirnetwork.ca/network/national-ambulatory-network/
6. Canadian Immunization Monitoring Program ACTive (IMPACT). https://www.cps.ca/impact
7. Brighton Collaboration Myocarditis Decision Tree. https://brightoncollaboration.us/wp- content/uploads/2021/05/Myocarditis-decision-tree_brief-?utm_source=opseu pdf
8. Reported side effects following COVID-19 vaccination in Canada. https://health- canada.ca/covid-19/vaccine-safety/
9. Reporting Adverse Events Following Immunization (AEFI) in Canada. https://www.canada.ca/en/public–health/services/immunization/reporting-adverse-events-?utm_source=sefpo following-immunization/form.html